Companies / Health Care
JNJ
Johnson & Johnson
Pharmaceuticals
PharmaceuticalsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health71
Growth44
Profitability99
Cash generation71
Balance sheet63
Dilution control76
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-27)5.9%Revenue growth (FY)6.0%Revenue CAGR (3y)5.6%Gross margin67.9%Operating margin—Net margin28.5%Free cash flow margin20.9%R&D / revenue0.1%Stock comp / revenue1.4%Net debt / operating cash flow1.31xCurrent ratio1.03Diluted share count change0.0%
| Fiscal year ending | FY 2022-01 | FY 2023-01 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Gross profit | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B |
| Net income | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Operating cash flow | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Capital expenditure | $3.7B | $4.0B | $4.5B | $4.4B | $4.8B |
| Free cash flow | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| R&D | $0 | $0 | $483M | $1.8B | $109M |
| Stock-based comp | $1.1B | $1.1B | $1.2B | $1.2B | $1.4B |
| Buybacks | $3.5B | $6.0B | $5.1B | $2.4B | $6.0B |
| Cash | $14.5B | $12.9B | $21.9B | $24.1B | $19.7B |
| Total debt | $38.0B | $42.7B | $32.3B | $40.1B | $51.9B |
| Equity | $74.0B | $76.8B | $68.8B | $71.5B | $81.5B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.